Gómez-Almaguer D, Ruiz-Argüelles GJ, Gutiérrez ACH, Jaime-Pérez JC

Language: Spanish
References: 41
Page: 291-297
PDF size: 63.76 Kb.

ABSTRACT

The feasibility of applying allogeneic cell –mediated therapy in conjunction with allogeneic hematopoietic cell transplantation following reduced –intensity conditioning, with minimal toxicity and no serious transplant-related complications, makes it possible to perform such procedures on an outpatient basis as well to offer a valid option for cure to elderly individuals and patients with less than optimal performance status. Based on available experience, clinical application of this innovative therapy may open new horizons for the treatment of patients with leukemia, lymphoma, myeloma and other diseases. Many patients can now benefit from the advantages of immunotherapy mediated by alloreactive donor lymphocytes, while minimizing transplant-related toxicity and mortality. This kind of transplant is making real progress in the world of transplantation.

REFERENCES

1. Storb R. Non-myeloablative allogeneic transplantation state of the art. Pediatr Transpl 2004; 8: 12-18.

2. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1998; 6: 1562-8.

3. Weiden PL, Fluornoy N, Thomas ED, et al. Antileukemic effect of graft versus host disease in human recipients of allogeneic marrow grafts. N Engl J Med 1979; 300: 1068–73.

4. Horowitz MM, Gale RP, Sondel PM, et al. Graft versus leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-62.

5. Weissman IL. Stem cells: units of development, units of regeneration and units in evolution. Cell 2000; 100: 157-68.

6. Weissman IL. Translating stem and progenitor cell biology to the clinic: barriers and opportunities. Science 2000; 287: 1442-6.

7. Childs R, Barrett J. Non-myeloablative allogeneic immunotherapy for solid tumors. Annu Rev Med 2004; 55: 459-75.

8. Slavin S. Reduced intensity conditioning or non-myeloablative stem transplantation: introduction, rationale and historic background. Semin Oncol 2004; 31: 1-3.

9. Saito T, Kanda Y, Kami, et al. Therapeutic potential of a reduced intensity preparative regimen for allogeneic transplantation with cladribine, busulfan and antithymocyte globulin against advanced/refractory leukemia/lymphoma. Clin Cancer Res 2002; 8:1014-20.

10. Childs R, Barrett J. Non-myeloablative allogeneic immunotherapy for solid tumors. Annu Rev Med 2004; 55: 459-75.

11. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after non-myeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234-41.

12. Slavin S, Nagler A, Naprastek E, et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematological diseases. Blood 1998; 91: 756-63.

13. Chakraverty R, Peggs K, Chapra R, et al. Limiting transplantation related mortality following unrelated donor stem cell transplantation by using a non-myeloablative conditioning regimen. Blood 2002; 99:1071-8.

14. Sandmaier BM, Maloney DG, Gooley TA et al. Low dose TBI conditioning for hematopoietic stem cell transplant (HSCT) from HLA-matched related donors for patients with hematological malignancies: influence of fludarabine or cytoreductive autografts on outcome. Blood 2002; 100: 145.

15. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematological malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-7.

16. Ruiz-Argüelles G, Gómez-Almaguer D. Breaking dogmata to help patients: non-myeloablative hematopoietic stem cell transplantation. Expert Opin Biol Ther 2004; 4: 1693-9.

17. Nusair S, Breuer R, Shapira M, et al. Low incidence of pulmonary complications following non-myeloablative stem cell transplantation. Eur Respir J 2004; 23: 440-5.

18. Diaconesu R, Flowers C, Storer B, et al. Morbidity and mortality with non-myeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1550-8.

19. Junghans C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following non-myeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Blood 2002; 99: 1978-85.

20. Junghans C, Boeckh M, Carter RA, et al. Incidence and outcome of cytomegalovirus infections following non-myeloablative compared with myeloablative allogeneic stem cell transplantation: a matched control study. Blood 2002; 99: 1978-85.

21. Weissinger F, Sandmaier BM, Maloney DG, et al. Decreased transfusion requirements for patients receiving non-myeloablative compared with conventional peripheral blood stem cell transplant from HLA-identical siblings. Blood 2001; 98: 3584-8.

22. Miel CM, Martin PJ, Leisenring W, et al. Graft versus host disease after non-myeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756-62.

23. Bacigalupo A. Third EBMT/AMGEN workshop on reduced-intensity conditioning allogeneic hematopoietic stem cell transplants (RIC-HSCT) and panel consensus. Bone Marrow Transpl 2004; 33: 691-6.

24. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer Leukemia Group B. N Engl J Med 1994; 331: 896-903.

25. Appelbaum FR, Clift RA, Buckner CD, et al. Allogeneic marrow transplantation for acute non-lymphoblastic leukemia after first relapse. Blood 1983; 61: 949-53.

26. Neiderwiser D, Maris M, Shizuru JA, et al. Low dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosupression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620-9.

27. Malladi RK, Peniket AJ, Norton AE, et al. Favorable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies. Eur J Haematol 2004; 73: 85-92.

28. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematological malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-400.

29. Hoelzer D, Thiel H, Loffler H et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71: 123-31.

30. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome. N Engl J Med 2001; 344: 1038-42.

31. Keating M, O‘Brien S, Lerner S, et al. Combination chemo-antibody therapy with fludarabine, cyclophosphamide, and rituximab achieves high CR rate in previously untreated chronic lymphocytic leukemia. Blood 2000; 96: 514.

32. Khouri, Lee M, Saliba R. Non-ablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation on survival. Experimental hematology 2004; 32: 28-35.

33. Van Beisen K, Sobocinski KA, Rowlings PA, et al. Allogeneic bone marrow transplantation for low grade lymphoma. Blood 1998; 92: 1832-6.

34. Gajewski JL, Phillips GL, Sobocinski KA, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin‘s disease. J Clin Oncol 1996; 14: 572-8.

35. Lalancette M, Rezvani K, Szydlo , et al. Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma: The EBMT experience. Blood 2000; 96: 204a.

36. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ruiz-Argüelles A, et al. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis. Bone Marrow Transpl 2000; 25: 131-3.

37. Gómez-Almaguer D, Ruiz-Argüelles GJ, Tarín-Arzaga LC, et al. Reduced-intensity stem cell transplantation in children and adolescents: the Mexican experience. Biol Blood Marrow Transpl 2003; 9: 157-61.

38. Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez-Rangel JD et al. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with acute leukemia eligible for conventional allografting: a prospective study. Leuk Lymphoma 2004; 45: 1191-5.

39. Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez-Morales E. Trasplante de células progenitoras hematopoyéticas. En: Góngora-Biachi R. (editor) Hematología: actualización 2004. Mérida, México: Ediciones de la Agrupación Mexicana para el Estudio de la Hematología A. C.; 2004, p. 139-48.

40. Sosa-Sánchez R, Córdova MS, Labardini JR, Chávez-Peón F. Trasplante de médula ósea en anemia aplástica. Reporte del primer caso en México. Rev Invest Clín Méx 1980; 32: 49-55.

41. Ruiz-Argüelles GJ, Gómez-Almaguer D, Gómez-Rangel JD, Vela Ojeda J, Karduss A, Cantú-Rodríguez OG, Jaime-Pérez JC, et al. Allogeneic hematopoietic stem cell transplantation with non-myeloablative conditioning in patients with myeloid leukemia: results of a prospective study of the Latin American Cooperative Onco Hematology Group (LACOGH). Blood 2004; 104 (Suppl 1): 373b.